Journal Sciences News
Veterinary Clinics of North America: Food Animal Practice
Available online 18 June 2018
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Publication date: Available online 18 June 2018
Source:The Lancet Author(s): Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan Background Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs). Methods We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs). We randomly assigned patients (2:2:1:1) by interactive response technology to receive once-daily oral extended-release upadacitinib 15 mg or 30 mg or placebo for 12 weeks, followed by upadacitinib 15 mg or 30 mg from week 12 onwards. The two separate primary endpoints were the proportions of patients achieving a 20% improvement in American College of Rheumatology criteria (ACR20) at week 12 and the proportion of patients achieving a 28-joint disease activity score using C-reactive protein (DAS28[CRP]) of 32 or less at week 12. Efficacy and safety analyses were done in the modified intention-to-treat population of all patients who received at least one dose of study drug. Data are presented up to week 24 of this ongoing study. The trial is registered with ClinicalTrials.gov (NCT02706847). Findings Between March 15, 2016, and Jan 10, 2017, 499 patients were randomly assigned (n=165 upadacitinib 15 mg; n=165 upadacitinib 30 mg; n=85 placebo then upadacitinib 15 mg; and n=84 placebo then upadacitinib 30 mg) and one patient was withdrawn from the 15 mg upadacitinib group before the start of study treatment. Mean disease duration was 132 years (SD 95); 235 (47%) of 498 patients had received one previous bDMARD, 137 (28%) had received two, and 125 (25%) had received at least three; 451 (91%) patients completed treatment up to week 12 and 419 (84%) patients completed treatment up to week 24. At week 12, ACR20 was achieved by 106 (65%; 95% CI 5772) of 164 patients receiving upadacitinib 15 mg and 93 (56%; 4964) of 165 patients receiving upadacitinib 30 mg compared with 48 (28%; 2235) of 169 patients receiving placebo (p<00001 for each dose vs placebo). DAS28(CRP) of 32 or less was achieved by 71 (43%; 95% CI 3651) of 164 patients receiving upadacitinib 15 mg and 70 (42%; 3550) of 165 patients receiving upadacitinib 30 mg versus 24 (14%; 920) of 169 patients receiving placebo (p<00001 for each dose vs placebo). Up to week 12, overall numbers of patients with adverse events were similar for the placebo group (95 [56%] of 169) and the upadacitinib 15 mg group (91 [55%] of 164), but higher in the upadacitinib 30 mg group (111 [67%] of 165). At week 12, the most common adverse events occurring in at least 5% of patients in any treatment group were upper respiratory tract infection (13 [8%] of 169 in the placebo group; 13 [8%] of 164 in the upadacitinib 15 mg group; ten [6%] of 165 in the upadacitinib 30 mg group), nasopharyngitis (11 [7%]; seven [4%]; nine [5%]), urinary tract infection (ten [6%]; 15 [9%]; nine [5%]), and worsening of rheumatoid arthritis (ten [6%]; four [2%]; six [4%]). The number of patients with serious adverse events was higher in the upadacitinib 30 mg group (12 [7%]) than in the upadacitinib 15 mg group (eight [5%]); no serious adverse events were reported in patients receiving placebo. More patients in the upadacitinib 30 mg group had serious infections, herpes zoster, and adverse events leading to discontinuation than in the upadacitinib 15 mg and placebo groups. During the placebo-controlled phase of the study, one case of pulmonary embolism, three malignancies, one major adverse cardiovascular event, and one death were reported in patients receiving upadacitinib; none were reported in patients receiving placebo. Interpretation Both doses of upadacitinib led to rapid and significant improvements compared with placebo over 12 weeks in patients with refractory rheumatoid arthritis. Funding AbbVie Inc.
Available online 18 June 2018
Mitochondrial medicine in the omics era
Publication date: Available online 18 June 2018
Source:The Lancet Author(s): Joyeeta Rahman, Shamima Rahman Mitochondria are dynamic bioenergetic organelles whose maintenance requires around 1500 proteins from two genomes. Mutations in either the mitochondrial or nuclear genome can disrupt a plethora of cellular metabolic and homoeostatic functions. Mitochondrial diseases represent one of the most common and severe groups of inherited genetic disorders, characterised by clinical, biochemical, and genetic heterogeneity, diagnostic odysseys, and absence of disease-modifying curative therapies. This Review aims to discuss recent advances in mitochondrial biology and medicine arising from widespread use of high-throughput omics technologies, and also includes a broad discussion of emerging therapies for mitochondrial disease. New insights into both bioenergetic and biosynthetic mitochondrial functionalities have expedited the genetic diagnosis of primary mitochondrial disorders, and identified novel mitochondrial pathomechanisms and new targets for therapeutic intervention. As we enter this new era of mitochondrial medicine, underpinned by global unbiased approaches and multifaceted investigation of mitochondrial function, omics technologies will continue to shed light on unresolved mitochondrial questions, paving the way for improved outcomes for patients with mitochondrial diseases.
Available online 18 June 2018
Transparency and accountability in AstraZeneca's access to health-care programmes
Publication date: Available online 18 June 2018
Source:The Lancet Author(s): Katarina Ageborg
1622 June 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Publication date: Available online 18 June 2018
Source:The Lancet Author(s): Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Heidi S Camp Background Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess the efficacy of upadacitinib in patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Methods This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide. Using interactive response technology, we randomly assigned patients receiving stable background csDMARDs (2:2:1:1) to receive a once-daily extended-release formulation of upadacitinib 15 mg or 30 mg, or placebo, for 12 weeks. Patients, investigators, and the funder were masked to allocation. After 12 weeks, patients taking placebo received 15 mg or 30 mg of upadacitinib once daily, according to the prespecified randomisation assignment. The primary endpoints were the proportion of patients at week 12 who achieved 20% improvement in American College of Rheumatology criteria (ACR20), and a 28-joint disease activity score using C-reactive protein (DAS28[CRP]) of 32 or less. We did efficacy analyses in the full analysis set of all randomly assigned patients who received at least one dose of study drug, and used non-responder imputation for assessment of the primary outcomes. This study is registered with ClinicalTrials.gov, number NCT02675426. Findings Between Dec 17, 2015, and Dec 22, 2016, 1083 patients were assessed for eligibility, of whom 661 were recruited and randomly assigned to receive upadacitinib 15 mg (n=221), upadacitinib 30 mg (n=219), or placebo (n=221). All patients received at least one dose of study drug, and 618 (93%) completed 12 weeks of treatment. At week 12, ACR20 was achieved by 141 (64%; 95% CI 5870) of 221 patients receiving upadacitinib 15 mg and 145 (66%; 6073) of 219 patients receiving upadacitinib 30 mg, compared with 79 (36%; 2942) of 221 patients receiving placebo (p<00001 for each dose vs placebo). DAS28(CRP) of 32 or less was met by 107 (48%; 95% CI 4255) patients receiving upadacitinib 15 mg and 105 (48%; 4155) patients receiving upadacitinib 30 mg, compared with 38 (17%; 1222) patients receiving placebo (p<00001 for each dose vs placebo). Adverse events were reported in 125 (57%) of 221 patients receiving upadacitinib 15 mg, 118 (54%) of 219 patients receiving upadacitinib 30 mg, and 108 (49%) of 221 patients receiving placebo. The most frequently reported adverse events (
1622 June 2018
Untangling the complications of diabetes
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): The Lancet
1622 June 2018
France may be back, but the old ways persist for INSERM
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): The Lancet
1622 June 2018
Living and dying with dementia
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): The Lancet
1622 June 2018
Long-term albumin in cirrhosis: is it the ANSWER?
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Guadalupe Garcia-Tsao
1622 June 2018
Diabetes mortality in the USA: winning the battle but not the war?
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Peter H Bennett
1622 June 2018
Screening men for AAA under magnification loupe in Sweden
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Stefan Acosta
1622 June 2018
Response to the Ebola virus disease outbreak in the Democratic Republic of the Congo
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): John N Nkengasong, Philip Onyebujoh
1622 June 2018
Troponin assays: developing indications
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Mark Mariathas, Nick Curzen
1622 June 2018
Sugar, tobacco, and alcohol taxes to achieve the SDGs
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Sugar Tobacco and Alcohol Taxes (STAX) GroupRobertMartenSowmyaKadandaleJohnButlerVictor MAguayoSvetlanaAxelrodNicholasBanatvalaDouglasBettcherLuisaBrumanaKentBuseSallyCasswellKatieDainAmandaGlassmanDavid LHeymannIlonaKickbuschPatricio VMarquezAndersNordstr
1622 June 2018
Offline: NCDs, WHO, and the neoliberal utopia
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Richard Horton
1622 June 2018
From Ireland to Northern Ireland: campaigns for abortion law
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Angel Li
1622 June 2018
Argentina votes on bill to legalise abortion up to 14 weeks
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Amy Booth
1622 June 2018
When genomics goes digital
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Evan D Muse, Ali Torkamani, Eric J Topol
1622 June 2018
Teeth and inequality: from past to present
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Richard G Watt
1622 June 2018
Chen Wang: new President of CAMS and PUMC
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Geoff Watts
1622 June 2018
Insomnia: a cultural history
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Kimberley Whitehead, Matthew Beaumont
1622 June 2018
The hospital reunion
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Marco De Ambrogi
1622 June 2018
Donald W Seldin
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Ivan Oransky, Adam Marcus
1622 June 2018
A herbal treatment for type 2 diabetes adulterated with undisclosed drugs
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Mia Steyn, Lewis Couchman, Gemma Coombes, Kenneth A Earle, Atholl Johnston, David W Holt
1622 June 2018
Endpoints in diabetes cardiovascular outcome trials
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Tejas Patel, Bereket Tesfaldet, Iffat Chowdhury, Anna Kettermann, James P Smith, Frank Pucino, Eileen E Navarro Almario
1622 June 2018
Cross-border collaboration and an advanced gastrointestinal endoscopic unit in Gaza
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Iyad Khamaysi, Khaled Matar
1622 June 2018
How gaps in policy implementation cause public health malpractice
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Joyce R Javier, Heather L Brumberg, Lee Sanders, Tamara S Hannon, Shetal Shah
1622 June 2018
Lancet Commission on pollution: action plans and human resource development in India
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): S Gangamma
1622 June 2018
Accelerating the evidence for new classes of long-lasting insecticide-treated nets
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Natacha Protopopoff, Mark Rowland
1622 June 2018
Department of Error
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138

1622 June 2018
Department of Error
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138

1622 June 2018
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Paolo Caraceni, Oliviero Riggio, Paolo Angeli, Carlo Alessandria, Sergio Neri, Francesco G Foschi, Fabio Levantesi, Aldo Airoldi, Sergio Boccia, Gianluca Svegliati-Baroni, Stefano Fagiuoli, Roberto G Romanelli, Raffaele Cozzolongo, Vito Di Marco, Vincenzo Sangiovanni, Filomena Morisco, Pierluigi Toniutto, Annalisa Tortora, Rosanna De Marco, Mario Angelico, Irene Cacciola, Gianfranco Elia, Alessandro Federico, Sara Massironi, Riccardo Guarisco, Alessandra Galioto, Giorgio Ballardini, Maria Rendina, Silvia Nardelli, Salvatore Piano, Chiara Elia, Loredana Prestianni, Federica Mirici Cappa, Lucia Cesarini, Loredana Simone, Chiara Pasquale, Marta Cavallin, Alida Andrealli, Federica Fidone, Matteo Ruggeri, Andrea Roncadori, Maurizio Baldassarre, Manuel Tufoni, Giacomo Zaccherini, Mauro Bernardi Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (
1622 June 2018
Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Edward W Gregg, Yiling J Cheng, Meera Srinivasan, Ji Lin, Linda S Geiss, Ann L Albright, Giuseppina Imperatore Background Large reductions in diabetes complications have altered diabetes-related morbidity in the USA. It is unclear whether similar trends have occurred in causes of death. Methods Using data from the National Health Interview Survey Linked Mortality files from 1985 to 2015, we estimated age-specific death rates and proportional mortality from all causes, vascular causes, cancers, and non-vascular, non-cancer causes among US adults by diabetes status. Findings From 198894, to 201015, all-cause death rates declined by 20% every 10 years among US adults with diabetes (from 231 [95% CI 201260] to 152 [146158] per 1000 person-years), while death from vascular causes decreased 32% every 10 years (from 110 [92122] to 52 [4856] per 1000 person-years), deaths from cancers decreased 16% every 10 years (from 44 [3255] to 30 [2833] per 1000 person-years), and the rate of non-vascular, non-cancer deaths declined by 8% every 10 years (from 77 [6392] to 71 [6675]). Death rates also declined significantly among people without diagnosed diabetes for all four major mortality categories. However, the declines in death rates were significantly greater among people with diabetes for all-causes (pinteraction<00001), vascular causes (pinteraction=00214), and non-vascular, non-cancer causes (pinteration<00001), as differences in all-cause and vascular disease death between people with and without diabetes were reduced by about a half. Among people with diabetes, all-cause mortality rates declined most in men and adults aged 6574 years of age, and there was no decline in death rates among adults aged 2044 years. The different magnitude of changes in cause-specific mortality led to large changes in the proportional mortality. The proportion of total deaths among adults with diabetes from vascular causes declined from 478% (95% CI 389588) in 198894 to 341% (314371) in 201015; this decline was offset by large increases in the proportion of deaths from non-vascular, non-cancer causes, from 335% (267421) to 465% (433500). The proportion of deaths caused by cancer was relatively stable over time, ranging from 16% to 20%. Interpretation Declining rates of vascular disease mortality are leading to a diversification of forms of diabetes-related mortality with implications for clinical management, prevention, and disease monitoring. Funding None.
1622 June 2018
Benefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Minna Johansson, Per Henrik Zahl, Volkert Siersma, Karsten Juhl J
1622 June 2018
Concentric circles in left atrium
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Xiaojun Xie, Jiao Bai
1622 June 2018
Type 1 diabetes
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Linda A DiMeglio, Carmella Evans-Molina, Richard A Oram Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the disease, including its genetics, epidemiology, immune and
Available online 14 June 2018
Genomic insights into the causes of type 2 diabetes
Publication date: 1622 June 2018
Source:The Lancet, Volume 391, Issue 10138 Author(s): Claudia Langenberg, Luca A Lotta Genome-wide association studies have implicated around 250 genomic regions in predisposition to type 2 diabetes, with evidence for causal variants and genes emerging for several of these regions. Understanding of the underlying mechanisms, including the interplay between
Available online 14 June 2018
Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial
Publication date: Available online 14 June 2018
Source:The Lancet Author(s): Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Alexandre Demoule, Martine Ferrandi
Available online 14 June 2018
Idiopathic nephrotic syndrome in children
Publication date: Available online 14 June 2018
Source:The Lancet Author(s): Damien G Noone, Kazumoto Iijima, Rulan Parekh The incidence of idiopathic nephrotic syndrome (NS) is 115169 per 100
Available online 14 June 2018
Immunological investigations empower transplant drug trials
Publication date: Available online 14 June 2018
Source:The Lancet Author(s): Edward K Geissler, James A Hutchinson
Available online 14 June 2018
Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial
Publication date: Available online 14 June 2018
Source:The Lancet Author(s): Gemma D Banham, Shaun M Flint, Nicholas Torpey, Paul A Lyons, Don N Shanahan, Adele Gibson, Christopher J E Watson, Ann-Marie O'Sullivan, Joseph A Chadwick, Katie E Foster, Rachel B Jones, Luke R Devey, Anna Richards, Lars-Peter Erwig, Caroline O Savage, Kenneth G C Smith, Robert B Henderson, Menna R Clatworthy Background B cells produce alloantibodies and activate alloreactive T cells, negatively affecting kidney transplant survival. By contrast, regulatory B cells are associated with transplant tolerance. Immunotherapies are needed that inhibit B-cell effector function, including antibody secretion, while sparing regulators and minimising infection risk. B lymphocyte stimulator (BLyS) is a cytokine that promotes B-cell activation and has not previously been targeted in kidney transplant recipients. We aimed to determine the safety and activity of an anti-BLyS antibody, belimumab, in addition to standard-of-care immunosuppression in adult kidney transplant recipients. We used an experimental medicine study design with multiple secondary and exploratory endpoints to gain further insight into the effect of belimumab on the generation of de-novo IgG and on the regulatory B-cell compartment. Methods We undertook a double-blind, randomised, placebo-controlled phase 2 trial of belimumab, in addition to standard-of-care immunosuppression (basiliximab, mycophenolate mofetil, tacrolimus, and prednisolone) at two centres, Addenbrooke's Hospital, Cambridge, UK, and Guy's and St Thomas' Hospital, London, UK. Participants were eligible if they were aged 1875 years and receiving a kidney transplant and were planned to receive standard-of-care immunosuppression. Participants were randomly assigned (1:1) to receive either intravenous belimumab 10 mg per kg bodyweight or placebo, given at day 0, 14, and 28, and then every 4 weeks for a total of seven infusions. The co-primary endpoints were safety and change in the concentration of naive B cells from baseline to week 24, both of which were analysed in all patients who received a transplant and at least one dose of drug or placebo (the modified intention-to-treat [mITT] population). This trial has been completed and is registered with ClinicalTrials.gov, NCT01536379, and EudraCT, 201100621556. Findings Between Sept 13, 2013, and Feb 8, 2015, of 303 patients assessed for eligibility, 28 kidney transplant recipients were randomly assigned to receive belimumab (n=14) or placebo (n=14). 25 patients (12 [86%] patients assigned to the belimumab group and 13 [93%] patients assigned to the placebo group) received a transplant and were included in the mITT population. We observed similar proportions of adverse events in the belimumab and placebo groups, including serious infections (one [8%] of 12 in the belimumab group and five [38%] of 13 in the placebo group during the 6-month on-treatment phase; and none in the belimumab group and two [15%] in the placebo group during the 6-month follow-up). In the on-treatment phase, one patient in the placebo group died because of fatal myocardial infarction and acute cardiac failure. The co-primary endpoint of a reduction in naive B cells from baseline to week 24 was not met. Treatment with belimumab did not significantly reduce the number of naive B cells from baseline to week 24 (adjusted mean difference between the belimumab and placebo treatment groups
Available online 13 June 2018
Sodium bicarbonate for severe metabolic acidaemia
Publication date: Available online 14 June 2018
Source:The Lancet Author(s): Jeffrey A Kraut, Nicolaos E Madias
Available online 11 June 2018
New-generation JAK inhibitors: how selective can they be?
Publication date: Available online 13 June 2018
Source:The Lancet Author(s): Guro L Goll, Tore K Kvien
Available online 11 June 2018
Department of Error
Publication date: Available online 11 June 2018
Source:The Lancet

915 June 2018
Department of Error
Publication date: Available online 11 June 2018
Source:The Lancet

915 June 2018
Nipah virus control needs more than R&amp;D
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): The Lancet
915 June 2018
Dolutegravir for HIV: a lesson in pregnancy safety research
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): The Lancet
915 June 2018
False hope with the Right to Try Act
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): The Lancet
915 June 2018
Direct oral anticoagulants for postoperative myocardial injury
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): Tom Adriaenssens, Peter Sinnaeve
915 June 2018
Take a blood pressure pill or undergo renal denervation?
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): Sverre E Kjeldsen, Murray D Esler

Renal denervation in uncontrolled hypertension: the story continues to unfold
Publication date: 915 June 2018
Source:The Lancet, Volume 391, Issue 10137 Author(s): Peter J Blankestijn, Michiel L Bots
view: 353

Zanflare F3 High Quality Waterproof Flashlight $7.99(65 % off)+Free shipping (Code:utyjwyyt)

Start: 24 Oct 2017 | End: 31 Mar 2018

Get on the list! Sign up for 15% OFF your first purchase, and a first look at all the latest trends at Laura.ca!

Start: 29 May 2017 | End: 01 May 2018

Say thanks with the perfect gift under $30!

Start: 01 May 2017 | End: 01 May 2018

Search All Amazon* UK* DE* FR* JP* CA* CN* IT* ES* IN* BR* MX
Booking.com B.V. is based in Amsterdam in the Netherlands. Ready for some statistics? Our 1,534,024 properties, including 860,482 holiday rentals, are located in 123,105 destinations in 229 countries and territories, and are supported internationally by 198 offices in 70 countries.
2013 Copyright Techhap.com Mobile version 2015 | PeterLife & company
Skimlinks helps publishers monetize editorial content through automated affiliate links for products.
Terms of use Link at is mandatory if site materials are using fully or particulary.
Were treated to the site administrator, a cup of coffee *https://paypal.me/peterlife
Yandex.ru